Cystic Fibrosis organisations in Australia provide support and services to people with Cystic Fibrosis (CF) and their carers and families. This is complemented by a commitment to research and a quality improvement program focussing on improved clinical care for people with CF.
Every four days a baby is born in Australia with cystic fibrosis (CF) and more than one million Australians are carriers of cystic fibrosis. Cystic Fibrosis Australia (CFA) is committed to improving clinical practice and patient outcomes through its quality improvement programmes and research with the aim of extending life expectancy from 37 to 50 years by 2025.
Cystic Fibrosis is a recessive genetic condition. It primarily affects the lungs and digestive system because of a malfunction in the exocrine system, responsible for producing saliva, sweat, tears and mucus.
In addition to working for a cure, Cystic Fibrosis Australia also provides support and advocacy to improve the lives of people with cystic fibrosis. Get involved by raising awareness about CF, participating in a fundraising event or volunteering.
Cystic Fibrosis Australia has established a consistent approach to advocacy across Australia and is now a subject matter expert for government, industry and the media.
The Australian Cystic Fibrosis Research Trust (ACFRT) is managed by Cystic Fibrosis Australia (CFA). Since 1989 it has funded more than 300 projects valued at over $6,000,000.
Visit the media room to browse through number of resources including media representatives, press releases and reports.
Clinical trials are listed below.
Anti-InfectiveEnrolling Location: USA
TEACH: Testing the effect of adding oral azithromycin to inhaled tobramycin in people with CF , protocol number TEACH-IP-15
This phase 2 study is taking place at multiple care centers across the US. It will look at the effect of adding oral azithromycin to inhaled tobramycin and will use placebo control.
Age:
12 Years and Older
Mutation(s):
No Mutation Requirement
FEV1% Predicted:
25 to 100%
Number of Visits:
6
Length of Participation:
16 weeks
Anti-InfectiveCompleted with results Location: USA
Arikace compared to Tobi® in people with CF with chronic Pseudomonas aueruginosa infections , protocol number NCT01315678 Insmed TR02-108
This study looked at the effectiveness, safety and tolerability of Arikayce compared to a currently available antibiotic, TOBI (tobramycin inhalation solution). This study was for people with CF with chronic lung infections.
6 Years and Older
25% or greater
11
6 months
Nutritional-GICompleted with results Location: USA
Efficacy and Safety of Ultrase MT20 in Children with CF and Pancreatic Insufficiency , protocol number Axcan UMT20CF07-01
This study looked at the effectiveness and safety of pancrelipase (ULTRASE MT20) in children who have CF and pancreatic insufficiency.
7 Years to 11 Years
No FEV1 Limit
33 days
Use of Utrase MT 12 Enzymes in Young Children with CF Related Pancreatic Insufficiency , protocol number Axcan UMT12CF08-01
This study evaluated the safety and effectiveness of pancrelipase (Ultrase MT 12) in young children with CF.
2 Years to 6 Years
4
30 days
Restore CFTR FunctionClosed to enrollment Location: USA
Phase 3 study of lumacaftor and ivacaftor in children with CF , protocol number Vertex VX13-809-011a
This study is taking place at multiple care centers across the U.S. It looked at the safety of lumacaftor in combination with ivacaftor, as well as how the body processes the drugs, in children with CF.
6 Years to 11 Years
Two copies F508del
24 days
Restore CFTR FunctionCompleted with results Location: USA
Phase 3 study of lumacaftor/ivacaftor in children with CF , protocol number Vertex VX15-809-115
This two-part, open-label study is taking place at multiple care centres across the US. It will look at the safety and effectiveness of lumacaftor/ivacaftor as well as how the body processes the drug, in children with CF.
2 - 5 Years
Two Copies F508del
40% or greater
32 weeks
Restore CFTR FunctionCompleted with results Location: Multiple care centres across the US
Phase 2 study of VX-659 combination drug in adults with cystic fibrosis. , protocol number VX16-659-101
This study is taking place at multiple care centres across the US. It will look at the safety and effectiveness of the drug VX-659.
18 years and older
No mutation requirement
8 weeks
A Study to evaluate tezacaftor/ivacaftor and ivacaftor in adults with cystic fibrosis and two copies of the F508del mutation. , protocol number Vertex VX16-661-114 NCT03150719
This study evaluated the safety, effectiveness and tolerability of the drug tezacaftor/ivacaftor (Symdeko®). This study was for people with CF ages 12 and older with two copies of the F508del CFTR modulation who had been taken off lumacaftor/ivacaftor (Orkambi®) due to respiratory side effects.
12 years and older
Two copies of F508del
25% - 90%
5
84 days
Mucociliary ClearanceCompleted with results Location: USA
Phase 2 study of VX-371 in people with CF who are currently taking lumacaftor/ivacaftor , protocol number Vertex VX-371-101
This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the inhaled drug VX-371 (formerly P-1037) and will use a placebo control.
40 to 90%
12
98 days
VX-661 alone and in combination with ivacaftor in people with cystic fibrosis , protocol number Vertex VX11-661-101
This study is taking place at multiple care centers across the U.S. It looked at the safety and effectiveness of VX-661 alone and in combination with ivacaftor, as well as how the drug works in the body, in people with CF.
18 Years and Older
9